Vident Investment Advisory, LLC I Teos Therapeutics, Inc. Transaction History

Vident Investment Advisory, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$13.02 - $22.62 $14,764 - $25,651	-1,134 Reduced 3.33%	32,887 $447,000
Q4 2022 Feb 14, 2023	SELL	$17.77 - $21.6 $586 - $712	-33 Reduced 0.1%	34,021 $664,000
Q3 2022 Nov 14, 2022	SELL	$18.6 - $27.25 $67,852 - $99,408	-3,648 Reduced 9.68%	34,054 $649,000
Q2 2022 Aug 15, 2022	BUY	$16.57 - $35.1 $144,473 - $306,036	8,719 Added 30.08%	37,702 $777,000
Q1 2022 May 16, 2022	BUY	$31.92 - $47.45 $154,173 - $229,183	4,830 Added 20.0%	28,983 $933,000
Q4 2021 Feb 14, 2022	BUY	$26.23 - $47.86 $633,533 - $1.16 Million	24,153 New	24,153 $1.13 Million

166

36.6M

1.95M

374K

Ticker ITOS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 35,575,300
Market Cap $257M
Description
Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or ...

Get notified when there are updates to the investment portfolio of Vident Investment Advisory, LLC, based on Form 13F filings with the SEC.

Stay updated on Vident Investment Advisory, LLC with notifications on news.